The federal government is widening a campaign to pull American drug prices toward what other wealthy nations pay, and the newest step reaches into state Medicaid programs. A fresh round of most-favored-nation agreements aimed at midsize biotech makers would let states buy certain outpatient medicines at the lower prices those companies charge abroad. Participation is optional for each state, and the discounts apply to specific drugs rather than an entire formulary. For the tens of millions of low-income and dual-eligible Americans covered by Medicaid, including many older adults, the move could reshape what a state pays for brand-name treatments.
How most-favored-nation pricing is meant to work
The most-favored-nation approach ties the price of a drug sold in the United States to the lowest net price the same manufacturer accepts in a group of comparison countries. Administration materials on most-favored-nation drug pricing point to a set of high-income nations, including Canada, France, Germany, Japan and the United Kingdom, as the benchmark. The underlying argument is that American buyers, long charged more than patients abroad for identical medicines, should not effectively subsidize lower prices across the rest of the developed world.
The strategy began with individual manufacturers rather than whole markets. An agreement with Regeneron earlier in 2026 established the template, and officials have since said more than a dozen makers have signed on to some version of the framework. Each deal is negotiated separately, with terms that can include direct-to-consumer sales channels and commitments on the launch prices of new products. The latest effort extends that one-by-one model into the Medicaid market, where states rather than individual patients would capture the savings on covered drugs.
State participation is the pivot point of the plan. Because Medicaid is administered jointly by the federal government and the states, each program can decide whether to adopt the foreign-aligned prices, which means the benefit will vary considerably by geography. Manufacturers, in turn, gain incentives that reportedly include relief from certain tariffs and possible exemptions from other Medicare discount pilots under development. That exchange, lower prices offered in return for regulatory breathing room, is what makes the arrangements attractive to companies that might otherwise resist cutting what they charge domestically.
Free retirement updates: Want plain-English help keeping more of your money in retirement? The free Retirement Shield newsletter covers the benefits, deadlines, and money mistakes that cost retirees, a couple times a week. Subscribe free.
The savings the administration is projecting
The government has attached large numbers to the effort. Officials have projected $529 billion in savings over a decade across the drug-pricing agreements, with a portion, roughly $64 billion, tied specifically to Medicaid. Those figures are administration estimates rather than settled outcomes, and they depend on how many manufacturers ultimately sign, how many states opt in, and whether the negotiated prices hold over time. Independent analysts have cautioned that projected savings of this magnitude rest on assumptions that may not fully materialize in practice.
The scale of Medicaid makes even partial adoption consequential. The program covers tens of millions of low-income Americans, and its prescription drug spending runs into the tens of billions of dollars each year, so trimming foreign-aligned discounts off brand-name medicines could free money for other services. State officials weighing the offer must balance those potential savings against the administrative work of adopting new pricing rules and the risk that manufacturers narrow the list of drugs that actually qualify for the lower rates.
Reporting on the plans to unveil the new biotech round described agreements aimed at midsize companies rather than the largest pharmaceutical firms, a segment where the administration may find more willing partners. As the agreements were being prepared, the specifics of which drugs and which states would be covered were still taking shape, according to the reporting on the coming deals. That leaves open how much of the headline savings will reach patients at the pharmacy counter rather than accruing to state budgets or being offset by higher prices elsewhere in the system.
What it could mean for coverage and costs
For older Americans, the practical effect depends heavily on coverage type. Dual-eligible beneficiaries, who qualify for both Medicare and Medicaid, stand to see the most direct impact if their state adopts the lower prices for the drugs they take regularly. Medicare enrollees without Medicaid would not be touched by this particular round, though the broader most-favored-nation push has separately been aimed at Medicare and commercial markets through other agreements that remain under negotiation and have not yet reached most pharmacy shelves.
Pharmaceutical companies have signaled mixed reactions to the campaign. Some have embraced the agreements as a way to secure tariff relief and more predictable rules, while others warn that pegging American prices to foreign benchmarks could discourage investment in new treatments. The industry has long argued that higher United States prices fund the research pipeline, a claim critics dispute by pointing to marketing budgets and stock buybacks. That tension sits underneath every deal the administration signs and shapes how far the model can spread.
The unresolved piece is durability. Voluntary deals can be renegotiated or abandoned, state participation can shift with budgets and politics, and the reference prices in foreign countries themselves move over time. Whether a patchwork of optional state agreements delivers the sweeping savings the administration has advertised, or settles into a narrower set of discounts on a handful of drugs, will not become clear until states begin deciding whether to opt in and manufacturers disclose the prices they have actually agreed to accept.
This article was researched and drafted with the assistance of artificial intelligence.
More Financial Reading
